Penumbra, Inc. Common Stock (NYSE:PEN):
Penumbra, Inc. to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum.
The company is up since yesterday’s close of $64.6.
Shares are trading at $65.85 a tad below the 50 day moving average which is $73.27 and which is marginally over the 200 day moving average of $63.72. The 50 day moving average was down by -10.12% and the 200 day average went up $2.13 or +3.34%.
Penumbra, Inc. Common Stock currently has a P/E ratio of 855.19 and the market cap is 2.04B. As of the latest earnings report the EPS was $0.08 and is estimated to be $-0.12 for the current year with 31,054,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.06 with next year’s EPS projected to be $0.07.
Brokerage firms have issued ratings on the stock of late. On October 17, 2016 BMO Capital initiated coverage on the stock with a rating of “Outperform”. Bank of America issued its first research report on the stock setting a rating of “Buy” and price target of $46.00.
On October 13 analysts at Wells Fargo started covering PEN with an initial rating of “Outperform”. Equity analyst JP Morgan added PEN to its research portfolio by announcing an initial rating of “Overweight”.
On October 13, 2015 Canaccord Genuity starting coverage on the stock giving it an initial rating of “Buy” and a price target of $48.00.